Dermal Cell News 2.28 August 8, 2016 | |
| |
TOP STORYClinical Trial Results Support Adalimumab Treatment for Painful Skin Condition The results of two Phase III clinical trials that led to FDA approval of adalimumab for treatment of the chronic inflammatory skin disease hidradenitis suppurativa were published. An inhibitor of the inflammatory protein tumor necrosis factor, adalimumab is the first such medication approved to treat the painful skin disorder. [Press release from Massachusetts General Hospital discussing online prepublication in The New England Journal of Medicine] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONDnmt3a and Dnmt3b Associate with Enhancers to Regulate Human Epidermal Stem Cell Homeostasis The genome-wide localization and function of endogenous Dnmt3a and Dnmt3b in adult stem cells are unknown. Scientists showed that in human epidermal stem cells, the two proteins bind in a histone H3K36me3-dependent manner to the most active enhancers and are required to produce their associated enhancer RNAs. [Cell Stem Cell] Abstract | Graphical Absrtact | Press Release Cutaneous Wound Healing Through Paradoxical MAPK Activation by BRAF Inhibitors Scientists showed how the BRAF inhibitor vemurafenib accelerates skin wound healing by inducing the proliferation and migration of human keratinocytes through extracellular signal-regulated kinase phosphorylation and cell cycle progression. [Nat Commun] Full Article The activities of two agonistic analogs of growth hormone releasing hormone, MR-409 and MR-502, were evaluated for their impact on proliferation and survival of primary human dermal fibroblasts. [Oncotarget] Full Article The Retinoid Agonist Tazarotene Promotes Angiogenesis and Wound Healing In vivo, Tazarotene enhanced the growth of mature and functional microvessels in Matrigel implants and wound healing models, and increased blood flow. In ear punch wound healing model, Tazarotene promoted tissue repair characterized by rapid ear punch closure with normal-appearing skin containing new hair follicles, and maturing collagen fibers. [Mol Ther] Abstract Targeted Alternative Splicing of TAF4: A New Strategy for Cell Reprogramming Investigators showed that manipulating alternative splicing is a highly potent strategy to produce cells for therapeutic applications. They demonstrated that silencing of hTAF4-TAFH activity of TAF4 converts human facial dermal fibroblasts to melanocyte-like cells. [Sci Rep] Full Article Scientists found E2F1 hinders skin wound healing by suppressing vascular endothelial growth factor expression, neovascularization, and macrophage recruitment. [PLoS One] Full Article SKIN CANCERS & DISORDERSLoss of Cohesin Complex Components STAG2 or STAG3 Confers Resistance to BRAF Inhibition in Melanoma Researchers showed that loss of stromal antigen 2 (STAG2) or STAG3, which encode subunits of the cohesin complex, in melanoma cells results in resistance to inhibitors of B-rad proto-oncogene, serine/threonine kinase (BRAF). [Nat Med] Abstract | Press Release Researchers evaluated whether the amount of neutrophil extracellular traps (NETs) is increased in psoriasis and determined the effect of NETs on human β-defensin-2HBD-2 production in epidermal keratinocytes. [Sci Rep] Full Article Investigators examined the effects of miR-15a on the proliferation and invasiveness of malignant melanoma cells in vitro, as well as the therapeutic effect of miR-15a in a mouse melanoma model. [Tumour Biol] Abstract | |
| |
REVIEWSEpithelial-Mesenchymal Transition in Tissue Repair and Fibrosis The authors summarize the role of epithelial-mesenchymal transition in physiologic repair and pathologic fibrosis of tissues and organs. [Cell Tissue Res] Abstract | Graphical Abstract Visit our reviews page to see a complete list of reviews in the dermal cell research field. | |
| |
SCIENCE NEWSProvectus Biopharmaceuticals, Inc. announced that a poster presentation titled “Intralesional rose bengal for Stage III and IV melanoma” is to be presented at the European Society for Medical Oncology 2016 Congress. [Press release from Provectus Biopharmaceuticals, Inc. discussing research to be presented at the European Society for Medical Oncology 2016 Congress, Copenhagen, Denmark] Press Release | |
| |
INDUSTRY NEWSAlmirall and Sun Pharma Enter into a License Agreement for Tildrakizumab in Europe for Psoriasis Sun Pharmaceutical Industries Ltd. and Almirall announced a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe. [Almirall] Press Release The Damon Runyon Cancer Research Foundation named 17 new Damon Runyon Fellows at its spring Fellowship Award Committee review. [Damon Runyon Cancer Research Foundation] Press Release | |
| |
POLICY NEWSThe FDA Is Prohibited from Going Germline A potentially renewable provision of the Consolidated Appropriation Act of 2016 forestalling the prospect of human germline modification was signed into law on December 18th, 2015. The provision has since been incorporated again into the House and Senate appropriation bills for the fiscal year. [ScienceInsider] Editorial US Agency Lifts Ban on Funding Human–Animal Hybrids Researchers in the United States will soon be able to resume creating chimaera-based projects. [Nature News] Editorial UK Research Assessment Should Boost Support for Principal Investigators A committee led by economist Nicholas Stern published recommendations on how to improve the United Kingdom’s Research Excellence Framework. [Nature News] Editorial Replications, Ridicule and a Recluse: The Controversy over NgAgo Gene-Editing Intensifies A controversy is escalating over whether a gene-editing technique proposed as an alternative to the popular CRISPR–Cas9 system actually works. [Nature News] Editorial Antibiotics Funding Splurge Gets Mixed Reception Antibiotics researchers are set to receive hundreds of millions of dollars from a new funding stream — but not everyone thinks the cash is being directed to the right place. [Nature News] Editorial Young Blood Antiaging Trial Raises Questions A startup company has launched the first clinical trial in the United States to test the antiaging benefits of young blood in relatively healthy people. But there’s a big caveat: It’s a pay-to-participate trial, a type that has raised ethical concerns before, most recently in the stem cell field. [ScienceInsider] Editorial Dispute over President’s Age Tears Pasteur Institute Apart Is 65 too old to stay at the helm of a major research center? That question is sowing division at the Pasteur Institute in Paris, Science has learned, and has plunged the 128-year-old institute, home to 1200 scientists and the place where HIV was first isolated, into a leadership crisis. [ScienceInsider] Editorial
| |
EVENTSNEW 12th International Skin Carcinogenesis Conference Visit our events page to see a complete list of events in the dermal cell community.
| |
JOB OPPORTUNITIESNEW PhD Position – Regulation of Keratinocyte Cell Death (University of Birmingham) NEW PhD Research Project – Human Tissue Interactions (University of Sheffield) Postdoctoral Fellow – Skin Biology (University of Cincinnati) Postdoctoral Fellow – Department of Pathology and Immunology (University of Geneva) Postdoctoral Researcher – Computational Biology (Helmholtz Association) PhD Studentship – Epithelial Stem Cell Biology (Curtin University) PhD Studentship – Quantitative Biology (University of Heidelberg) Postdoctoral Fellow – Skin Carcinogenesis (Inserm) Postdoctoral Positions – Cell, Developmental & Cancer Biology (Oregon Health & Science University) Postdoctoral Fellow – Tissue Regeneration (US Army Institute of Surgical Research) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Dermal Cell News Volume 2.28 | Aug 8 2016